Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Single Dose, Randomised, Double-blind, Two-way Crossover, Glucose Clamp Study Investigating the Pharmacodynamics, Pharmacokinetics and Safety of Arecor Rapid-acting Concentrated Insulin Aspart (AT278) in Comparison to Insulin Aspart NovoRapid in Participants With Type 1 Diabetes Mellitus (T1DM).

Next Previous
X
Search
Trial Profile

Phase 1 Single Dose, Randomised, Double-blind, Two-way Crossover, Glucose Clamp Study Investigating the Pharmacodynamics, Pharmacokinetics and Safety of Arecor Rapid-acting Concentrated Insulin Aspart (AT278) in Comparison to Insulin Aspart NovoRapid in Participants With Type 1 Diabetes Mellitus (T1DM).

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin aspart (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Arecor

    • Most Recent Events

    • 30 Jan 2023 Results published in the Diabetes Care
    • 23 Sep 2022 Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
    • 28 Apr 2022 According to an Arecor media release, the data from this study was presented at the 15th International Advanced Technologies and Treatments for Diabetes (ATTD) meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top